Drug Discovery

Loading the player...

VISION Post Non-cardiac Surgery Troponin Levels May Identify Heart Damage

Patrick O'Gara, MD interviews Mark Creager, MD immediate past president of the American Heart Association, about the results of the VISION Trial.

Science NewsView All

Science News from ACC17
Exclusive video discussions and data summaries of the most noteworthy science presented at ACC.17 in Washington, D.C. from March 17-19, 2...
Bradycardia Guideline - Systematic Review Question for Stakeholder Feedback
03/13/2017 | Accepted March 13 through March 27, 2017 -- Bradycardia Guideline - Systematic Review Question for Stakeholder Feedback

Featured Science from Thursday, Feb. 23

Thursday Main Event
11:00 a.m. to 12:00 p.m. - Hall C

Intensive Versus Guideline Antiplatelet Therapy For Preventing Recurrence In Patients With Acute Ischaemic Stroke Or TIA: Main Results From The Triple Antiplatelets For Reducing Dependency In Ischaemic Stroke (TARDIS) Trial
Philip M Bath | University of Nottingham, Nottingham, United Kingdom

RESULTS: Neutral results: stroke recurrence was not lower; bleeding increased with intensive antiplatelet therapy.


Cilostazol Versus Aspirin in Ischemic Stroke Patients With Intracerebral Hemorrhage or Multiple Microbleeds
Sun U. Kwon Sr. | Asan Medical Center, Seoul, Republic of Korea

RESULTS: Stroke rates were less with cilostazol than aspirin, but more MI occurred with cilostazol.


Resumption of Oral Anticoagulation After Intracerebral Hemorrhage is Associated With Decreased Mortality and Favorable Functional Outcome
Alessandro Biffi | Massachusetts General Hospital, Boston, MA

RESULTS: The favorable findings in both non-lobar and lobar ICH indicate a need for more randomized clinical trials.


Efficacy and Safety of Nimodipine in Vascular Mild Cognitive Impairment: A Randomized Placebo Controlled Trial
Huaguang Zheng | Capital Medical University, Beijing Tiantan Hospital, Beijing, China

RESULTS: Nimodipine was no better than placebo in preventing cognitive decline.

Late-Breaking Science Oral Abstracts I
1:30 p.m. to 3:00 p.m. - Grand Ballroom B

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack of Atherosclerotic Origin
Pierre Amarenco | Paris Diderot University, Paris, France

RESULTS: At 90 days, ticagrelor prevented more strokes, MIs, and deaths than aspirin in patients with acute stroke or transient ischemic attack of atherosclerotic origin.


Safety and Feasibility of Combination of Ticagrelor and Aspirin in Patients With Minor Stroke or TIA :Interim Analyses of the Platelet Reactivity in Acute Stroke or Transient Ischemic Attack (PRINCE) Trial
Yilong Wang | Capital Medical University, Beijing Tiantan Hospital, Beijing, China

RESULTS: Adverse events led to more medication discontinuation in the ticagrelor arm compared to the clopidogrel arm.


Rapid Increase in Endovascular Thrombectomy for Acute Ischemic Stroke in the United States: Data From Get With the Guidelines-Stroke
Eric E Smith | University of Calgary, Calgary, AB, Canada

RESULTS: Randomized controlled trial results and updated guidelines prompted more use of endovascular thrombectomy.


Interhospital Transfer Prior to Thrombectomy is Associated With Delayed Treatment and Worse Outcome in the STRATIS Registry
Michael T Froehler | Vanderbilt University, Nashville, TN

RESULTS: Strategies to spot large vessel occlusion and use endovascular-capable centers may improve outcomes.

ATVB | PVD 2017 Scientific Sessions

Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease 2017 Scientific Sessions
May 4-6, 2017
Hyatt Regency Minneapolis
Minneapolis, Minnesota
 

Learn about ATVB|PVD 2017

Professional Online Network

Related Councils

Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB)

Steven R. Lentz, MD, PhD, FAHA

The Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) contributes to the mission and objectives of the American Heart Association (AHA) through efforts in the fields of arteriosclerosis, thrombosis and vascular biology. The council advances and coordinates research, addresses prevention, improves methods for diagnosis and treatment, and works actively with other organizations concerned with these issues. The council disseminates reliable information related to these fields through its annual conference, many awards and lectures, and the AHA's journal, Arteriosclerosis, Thrombosis, and Vascular Biology.

Steven R. Lentz, MD, PhD, FAHA
Chair, Council on Arteriosclerosis, Thrombosis and Vascular Biology

ATVB|PVD Scientific Sessions       Arteriosclerosis, Thrombosis, and Vascular Biology       ATVB Council Awards

Council on Clinical Cardiology (CLCD)

Ileana L. Piña, MD, MPH, FAHA, FACC

The purpose of the Council on Clinical Cardiology (CLCD) is to achieve the objectives of the American Heart Association (AHA) in the field of clinical cardiology, to promote excellence in clinical care and to foster the professional development and education of clinical cardiologists. Through council-sponsored symposia, panels and scientific conferences, members can access new developments in the field and interpret and promote clinical cardiology to professional and lay audiences.

Ileana L. Piña, MD, MPH, FAHA, FACC
Chair, Council on Clinical Cardiology

Scientific Sessions       Circulation       CLCD Council Awards

Council on Functional Genomics and Translational Biology (FGTB)

Svati Shah, MD, MS, MHS, FAHA

The mission of the American Heart Association (AHA) Council on Functional Genomics and Translational Biology (FGTB) is to advance discoveries from genetics, systems and translational biology and to facilitate their application in global cardiovascular health and disease.

Svati Shah, MD, MS, MHS, FAHA
Chair, Council on Functional Genomics and Translational Biology

Scientific Sessions       Circulation: Cardiovascular Genetics      FGTB Council Awards